Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

14.35 EUR

-1.03 %

5,596 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-1.03 %
-1.37 %
+9.54 %
+71.65 %
+81.65 %
+139.17 %
+241.67 %
+210.65 %
-97.63 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
103.51M EUR
Turnover
25.49K EUR
P/E (adj.) (25e)
25.4
EV/EBIT (adj.) (25e)
24.7
P/B (25e)
13.13
EV/S (25e)
6.69
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.50 EUR
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Brainlab recently on LinkedIn…Birkenbacher; A new chapter for nTMS in neurosurgery—Nexstim NBS 6 is now CE marked and FDA cleared for pre-surgical brain mapping. NBS 6 brings with it a redesigned, intuitive user interface, guided workflow, and streamlined connectivity to systems ...
12/1/2025, 6:27 PM
by Taitoo
28
It looks like it’s going down to the wire again, but that’s how it went last year too:
18 hours ago
by Kyhnykeisari
21
Biostock – 3 Dec 25 Nexstim: from Helsinki to a global brain revolution Finnish Nexstim's vision is to offer personalized diagnostics and therapy for serious brain diseases and disorders. To achieve this, it has developed a non-invasive technology for brain stimulation. The treatment...
yesterday
by Kyhnykeisari
19
canhealth.com CABHI awards $2.8M to advance the brain economy | Canadian Healthcare Technology TORONTO - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, has allocated $2.8 million CAD in funding to eight early- to mid-stage researchers and companies through...
yesterday
by Jatast
17
Skandinaviska Enskilda Banken Ab (publ) Helsinki Branch added 25,922 shares last month. That information does not reach the ultimate owner, but one nuance is that Brainlab’s holdings are also in that same nominee register. At an average price of €14.50, the acquisition of those shares...
12/2/2025, 7:43 AM
by Kyhnykeisari
17
linkedin.com #neuromodulation #alzheimers #defaultmodenetwork #medtech #ctad25 | Sinaptica... Today at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, Giacomo Koch, MD, PhD, Sinaptica scientific co-founder, and Lisa Fosdick, MS, Chief Clinical & Strategy Officer...
12/2/2025, 5:27 PM
by Jatast
9
It seems there has been an update to that shareholder register, and that’s why it looks wrong. Leena still has the same number of shares as before, but her first name and last name have just swapped places.
12/2/2025, 8:40 AM
by Kyhnykeisari
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.